Product Description
Mechanisms of Action: Radioactive Agent
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: ZS Pharma, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hyperkalemia
Phase 2: Hyperkalemia|Kidney Failure, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01493024 |
ZS-002 | P2 |
Completed |
Kidney Failure, Chronic|Hyperkalemia |
2012-05-31 |
2019-03-19 |
Treatments |
|
NCT02088073 |
ZS-004 | P3 |
Completed |
Hyperkalemia |
2014-08-31 |
2019-03-20 |
Treatments |
|
NCT01737697 |
ZS-003 | P3 |
Completed |
Hyperkalemia |
2013-10-31 |
2019-03-19 |
Treatments |